Genetically modified tumor-targeted bacteria with reduced virulence
AssigneesVion Pharmaceuticals, Inc., Yale University
InventorsDavid Bermudes, Kenneth Brooks Low
Life of this patent
Estimating the term…
Abstract
The present invention is directed to mutant Salmonella sp. having a genetically modified msbB gene in which the mutant Salmonella is capable of targeting solid tumors. The present invention further relates to the therapeutic use of the mutant Salmonella for growth inhibition and/or reduction in volume of solid tumors.
Claims13
A mutant Salmonella sp. comprising a genetically modified msbB gene in a tumor targeting mutant Salmonella which is capable of inhibiting growth of a solid tumor when administered in vivo, wherein said mutant Salmonella sp. expresses an altered lipid A molecule compared to a wild-type Salmonella sp., and induces TNF.alpha. expression at a level less than that induced by a wild type Salmonella sp.
Dependencies are inferred from the claim text.